Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
With late-stage trial success, venture funding and next-generation alpha emitters on the way, targeted radiotherapy drugs are finally “getting the attention they deserve.”
Researchers hope that antisense oligo clinical trial failures in Huntington’s will shed light on mechanism and drug biodistribution and galvanize ongoing drug development efforts.
An innovative program addresses the need for support, encouragement and guidance on the part of women scientists in the early years of their career, during their PhD.
A citation map connecting patents to biomedical publications provides insights that can be used to better evaluate productivity, diversity and translational impact.
Nature Biotechnology asks a selection of leaders from across biotech to look at the future of the sector and make some predictions for the coming years.
Cytokines are problematic drugs, but Stanford structural immunologist Chris Garcia has engineered creative solutions that his company will begin testing this year in cancer
New initiatives in N-of-1 drug development and clinical trial design offer the possibility of therapies for ultra-rare disease patients who have been long neglected by the drug industry.
The not-for profit foundation n-Lorem seeks to provide experimental antisense oligonucleotide treatments to patients with ultra-rare disease free for their entire lifetime.
